Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 228
Recruiting: 123
Ph III recruiting: 18
Growth YoY: +39.5%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (82)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05111626	Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102)	terminated	Phase 3	515	AmgenINDUSTRY	29	Sep 10, 2026	clinicaltrials
NCT03042169	Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer(SURGIGAST)	terminated	Phase 3	6	University Hospital, LilleOTHER